NCT04983823

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 820 (estimated)
• Sponsor: Baker Heart and Diabetes Institute · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Accepted

Summary

This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old. The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.

Detailed description

Participants enrolled in this study will be randomized to a cardio-COVID disease management plan (CC-DMP) that involves the use of VO2 testing and surveillance imaging to detect reduced functional capacity and subclinical left ventricular dysfunction (LVD), clinical review to ensure optimal risk factor control and cardio-protection and exercise intervention. The program will be delivered over a period of 24 months. The outcome from this study will show that subclinical LVD is common among COVID-19 survivors, and a CC-DMP is feasible in reducing HF risk factors in this sub group of survivors.

Conditions

• Heart Failure

Interventions

Type	Name	Description
OTHER	Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)	A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
OTHER	Usual care	This will be provided by participants' usual healthcare professional(s).

Timeline

• Start date: 2021-11-18
• Primary completion: 2025-07-30
• Completion: 2025-12-30
• First posted: 2021-07-30
• Last updated: 2025-10-03

Locations

1 site across 1 country: Australia